Esophageal Diseases  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

45 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00004127: Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach

Completed
2
35
US
FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
University of Chicago, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
10/02
08/03
NCT00040859: Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Completed
2
48
US
capecitabine, oxaliplatin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
01/05
04/08
NCT00256269: Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Terminated
2
4
US
Oxaliplatin, Irinotecan
University of California, Irvine, Sanofi
Esophageal Cancer, Gastroesophageal Cancer
02/07
02/07
NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Completed
2
44
US
BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875.
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
05/08
09/10
NCT00259402: Oxaliplatin in Esophagus Cancer (Advanced) 1st Line

Completed
2
41
Europe
Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
Sanofi
Esophageal Neoplasms
10/08
10/08
NCT00084617: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

Completed
2
39
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, capecitabine, CAPE, Ro 09-1978/000, Xeloda
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
10/08
12/08
NCT00711412: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

Completed
2
44
US
Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery
Northwestern University
Esophageal Cancer
05/09
01/13
NCT00086996: S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

Completed
2
98
US
fluorouracil, 5-FU, oxaliplatin, eloxatin, conventional surgery, radiation therapy
Southwest Oncology Group, National Cancer Institute (NCI)
Esophageal Cancer
08/09
08/11
NCT00737373 / 2006-006936-24: Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Completed
2
143
Europe
Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid
Krankenhaus Nordwest
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
12/09
03/11
NCT00448760: Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

Completed
2
29
US
Docetaxel, Taxotere, Floxuridine, FUdR, Leucovorin, Oxaliplatin, Microarray analysis, reverse transcriptase-polymerase chain reaction, Conventional surgery
University of Miami
Esophageal Cancer
04/10
04/10
NCT00515216: Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

Completed
2
26
US
5-fluorouracil, 5-FU, Fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Wellcovorin, citrovorum factor, folinic acid, 5-formyl tetrahydrofolate
Vanderbilt University, University of Alabama at Birmingham, University of North Carolina, Washington University School of Medicine, National Cancer Institute (NCI)
Stomach Neoplasms, Esophageal Neoplasms
08/11
11/13
NCT01262482 / 2008-004223-27: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
41
Europe
Oxaliplatin, Sorafenib
Grupo Espanol Multidisciplinario del Cancer Digestivo
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)
10/11
12/11
NCT00551759: Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Terminated
2
22
US
5-Fluorouracil, 5-FU, Fluorouracil, Adrucil, Efudex, Oxaliplatin, Trans-l-diaminocyclohexane oxalatoplatinum, Cis-[oxalato (trans-I-1,2-diaminocyclohexane) platinum(II)], l-OHP, Eloxatin, Eloxatine, Dacplat, 5R96669, Cetuximab, Erbitux, C225, Docetaxel, Taxotere, RP 56976, Surgery, Radiotherapy
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Esophageal Cancer
10/11
02/14
NCT01605305: Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer

Completed
2
60
RoW
FOLFOX6
Fudan University
Esophageal Squamous Cell Carcinoma
01/12
01/12
FLOT3, NCT00849615: Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Completed
2
252
Europe
Docetaxel, 5-Fluorouracil, Oxaliplatin, folinic acid
Krankenhaus Nordwest
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
01/12
01/16
NCT00601705: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

Completed
2
61
US
cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
03/12
01/15
NCT00982592: Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Completed
2
124
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, placebo, PLCB, vismodegib, Erivedge, GDC-0449, Hedgehog antagonist GDC-0449, laboratory biomarker analysis
National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
04/12
10/14
NCT00470184: Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

Completed
2
41
US
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy
Roswell Park Cancer Institute, National Comprehensive Cancer Network
Esophageal Cancer
10/12
 
NCT00217581: Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Completed
2
39
US
Bevacizumab, Avastin, Docetaxel, Taxotere, Oxaliplatin, Eloxatin
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
11/12
01/13
NCT01710592 / 2006-003332-29: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Completed
2
35
Europe
Epirubicin, Oxaliplatin, Capecitabine, Docetaxel
Cancer Trials Ireland
Gastro Oesophageal Cancer
12/12
 
NCT00525915: Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Completed
2
126
US
5-Fluorouracil, 5-FU, Adrucil, Efudex, Oxaliplatin, Eloxatin, Radiation Therapy, RT, XRT, Surgery
M.D. Anderson Cancer Center, Sanofi
Esophageal Cancer, Gastroesophageal Cancer
03/13
03/13
NCT01246960: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
168
US
Ramucirumab, LY3009806, IMC-1121B, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil, 5-FU
Eli Lilly and Company
Stomach Cancer, Esophageal Cancer
09/13
05/14
NCT00938470: Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed
2
73
US
capecitabine, docetaxel, fluorouracil, oxaliplatin, radiation therapy, therapeutic conventional surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
12/13
03/18
XAGastric, NCT00447330: Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Checkmark capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Mar 2013 - Mar 2013: capecitabine, oxaliplatin, and bevacizumab in met esophagogastric adenocarcinomas
Completed
2
60
US
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Duke University, Hoffmann-La Roche, Sanofi, Genentech, Inc.
Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
01/14
07/14
NCT02607982: CCRT for Esophageal Cancer.

Completed
2
34
RoW
Paclitaxel, Oxaliplatin, Radiotherapy
Hangzhou Cancer Hospital
Esophageal Cancer, Concurrent Chemoradiotherapy, Oxaliplatin, Paclitaxel
06/14
11/15
NCT01372202: CHFR Methylation Status Esophageal Cancer Study

Terminated
2
31
US
Paclitaxel, Abraxane, Taxol, Cisplatin, Platinol, Oxaliplatin, Eloxatin, 5-Fluorouracil, 5-FU, Adrucil, Carac, Efudex, Fluorouracil, Radiotherapy, IMRT, Esophagectomy, Resection
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
Esophageal Cancer
06/14
10/14
HerFLOT, NCT01472029 / 2011-001507-13: Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
53
Europe
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy
AIO-Studien-gGmbH, Roche Pharma AG
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
08/14
09/16
NCT02879227: Radiochemotherapy in Elderly Patients With Oesophagus Cancer

Completed
2
23
Europe
Cisplatin, Arm Cisplatin, Oxaliplatin, Arm Oxaliplatin
Centre Hospitalier Universitaire de Besancon
Esophagus Cancer
12/14
12/14
NCT01178944: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Completed
2
35
US
Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX
Roswell Park Cancer Institute, National Cancer Institute (NCI), National Comprehensive Cancer Network
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma
01/15
11/15
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
2
22
US
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery.
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University
Esophageal Cancer, Gastric Cancer
02/15
02/15
NCT02344810: C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Withdrawn
2
0
US
c-Met inhibitor AMG 337, AMG 337, AMG337, placebo, PLCB, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis
Eastern Cooperative Oncology Group, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
03/15
 
NCT01932580: Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma

Completed
2
10
Canada
FLOT (5-fluorouracil, oxaliplatin, docetaxel), Oxaliplatin: Eloxatin, Docetaxel: Taxotere
McGill University
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
06/15
06/15
NCT01870791 / 2011-003950-24: Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer

Terminated
2
21
Europe
Omegaven, Omega-3 fish oil
University Hospitals, Leicester
Esophageal Neoplasm, Gastric Neoplasm
12/15
12/15
NCT02392377: Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Terminated
2
1
US
Paclitaxel, Anzatax, TAX, Carboplatin, Oxaliplatin, Leucovorin Calcium, CF, Fluorouracil, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RT, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
12/15
12/15
E-DIS, NCT01248299 / 2010-021439-16: Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.

Terminated
2
105
Europe
FU-CDDP, Fluoro-uracil+CisPlatin, LV5FU2-CDDP, Elvorin+Fluoro-uracil+CisPlatin, FOLFOX, Oxaliplatin+Fluoro-uracil+Elvorin, TPF, Docetaxel+CisPlatine+Fluoro-uracile, Best Supportive Care, antalgic treatment, nutritional support, ...
Centre Oscar Lambret, National Cancer Institute, France
Squamous Cell Carcinoma of Esophagus
01/16
01/17
FluoHeart, NCT02216149 / 2013-003976-11: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Terminated
2
20
Europe
S-1, Teysuno, tegafur/gimeracil/oteracil, Capecitabine, Xeloda, Oxaliplatin, Eloxatin
Heikki Joensuu
Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer, Rectum Cancer
08/18
08/18
NCT02943603: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Withdrawn
2
0
US
mFLOFOX6 + pembrolizumab
Weijing Sun, MD, FACP
Adenocarcinoma, Stomach Cancer
01/19
07/19
NCT00093652: Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Terminated
1/2
US
gefitinib, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy
Roswell Park Cancer Institute
Esophageal Cancer
05/06
 
NCT00732745: Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction

Checkmark
Apr 2013 - Apr 2013: 
Terminated
1/2
9
US
docetaxel, oxaliplatin, vandetanib, placebo
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
06/10
 
EOXP, NCT00667420: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Terminated
1/2
17
US
panitumumab, epirubicin, oxaliplatin, xeloda
Massachusetts General Hospital
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
06/11
06/14
POXX, NCT00578071: Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

Completed
1/2
29
US
Panitumumab, Capecitabine, Xeloda, Oxaliplatin, Radiation Therapy (RT)
Brian Czito, Amgen
Cancer of the Esophagus
07/11
06/12
NCT00374985: Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Completed
1/2
25
Europe
Docetaxel, Oxaliplatin, Radiotherapy
Johannes Gutenberg University Mainz
Esophageal Neoplasms, Stomach Neoplasms
09/13
09/13
NCT01231399: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
1/2
6
US
fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Adrucil, Efudex, FU, leucovorin calcium, calcium folinate, CF, CFR, citrovorum factor, LV, Wellcovorin, oxaliplatin, 1-OHP, Dacotin, Dacplat, diaminocyclohexane oxalatoplatinum, Eloxatin, L-OHP, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling
City of Hope Medical Center, National Cancer Institute (NCI)
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
07/16
07/16
ACTION, NCT02273713: The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma

Completed
1/2
154
Europe
Nab-paclitaxel, Abraxane
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celgene Corporation
Esophageal Cancer, Toxicity
03/17
03/17
NCT01490749: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Completed
1/2
17
US
RAD001, Everolimus, XELOX, Oxaliplatin and capecitabine, Eloxatin and Xeloda, Carboplatin, Paraplatin, Radiation
Emory University, Novartis
Esophageal Cancer, Neoplasms, Esophageal
02/19
02/19

Download Options